Caelus Health recently started a key clinical trial in individuals suffering from Metabolic Syndrome or pre-diabetes; these individuals are at risk of developing Type 2 diabetes.
The microbiome product based on a single micro-organism (named A. soehngenii) may delay or even prevent the onset of diabetes. The trial is a final step in the development and registration of this product as a food supplement following successful completion of the previous study.
Caelus Health was established in close cooperation with Wageningen University.
Oxygen is of vital importance. In critical situations, the management of oxygenation is difficult. Many interventions during and after surgery and in intensive care are aimed at maintaining oxygen levels in organ cells. Until now, only indirect information about this has been available. As a result, what is the best treatment for the individual patient […]News
Raoul Frese – assistant professor at the Faculty of Science, Biophysics Photosynthesis/Energy at Vrije Universiteit Amsterdam – has received the last Physics2Market subsidy to further develop material to substitute mineral wool in greenhouses. Greenhouse horticulture is a highly controlled way to grow crops and flowers in a semi-artificial environment. This main industry in the Netherlands […]News
Halleh Ghorashi, Jeroen Kluck en Hergen Spits winnaars Impact Award 2021!News